MX2020010390A - Profarmacos de antagonistas de c5ar biciclicos fusionados. - Google Patents

Profarmacos de antagonistas de c5ar biciclicos fusionados.

Info

Publication number
MX2020010390A
MX2020010390A MX2020010390A MX2020010390A MX2020010390A MX 2020010390 A MX2020010390 A MX 2020010390A MX 2020010390 A MX2020010390 A MX 2020010390A MX 2020010390 A MX2020010390 A MX 2020010390A MX 2020010390 A MX2020010390 A MX 2020010390A
Authority
MX
Mexico
Prior art keywords
prodrugs
bicyclic
fused
c5ar antagonists
c5ar
Prior art date
Application number
MX2020010390A
Other languages
English (en)
Inventor
Venkat Reddy Mali
Rebecca M Lui
Yibin Zeng
Pingchen Fan
Penglie Zhang
Rajinder Singh
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2020010390A publication Critical patent/MX2020010390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona, inter alia, Compuestos de las fórmulas IA, IB, IC, IIA, IIB y IIC (ver Fórmulas) o sales farmacéuticamente aceptables de los mimos que son moduladores del receptor de C5a. También se proporcionan composiciones farmacéuticas y métodos de usos incluyendo el tratamiento de enfermedades o trastornos que involucran la activación patológica de C5a y aplicaciones no farmacéuticas.
MX2020010390A 2018-04-02 2019-04-01 Profarmacos de antagonistas de c5ar biciclicos fusionados. MX2020010390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862651512P 2018-04-02 2018-04-02
PCT/US2019/025165 WO2019195159A1 (en) 2018-04-02 2019-04-01 PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Publications (1)

Publication Number Publication Date
MX2020010390A true MX2020010390A (es) 2021-01-15

Family

ID=68054774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010390A MX2020010390A (es) 2018-04-02 2019-04-01 Profarmacos de antagonistas de c5ar biciclicos fusionados.

Country Status (15)

Country Link
US (2) US20190300526A1 (es)
EP (1) EP3773563A4 (es)
JP (1) JP7337833B2 (es)
KR (1) KR20200139751A (es)
CN (1) CN111954525B (es)
AR (1) AR114464A1 (es)
AU (1) AU2019246969A1 (es)
BR (1) BR112020019822A2 (es)
CA (1) CA3095184A1 (es)
IL (1) IL277608B2 (es)
MA (1) MA52245A (es)
MX (1) MX2020010390A (es)
SG (1) SG11202009588PA (es)
TW (1) TWI827590B (es)
WO (1) WO2019195159A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
CN111406051A (zh) 2017-09-03 2020-07-10 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环
BR112020012270A2 (pt) 2017-12-22 2020-11-24 Chemocentryx, Inc. compostos de anel 6,5-fundido substituído por diarila como inibidores de c5ar
US10759807B2 (en) 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
MX2020010390A (es) 2018-04-02 2021-01-15 Chemocentryx Inc Profarmacos de antagonistas de c5ar biciclicos fusionados.
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
ES2921360T3 (es) 2019-12-19 2022-08-24 Active Biotech Ab Compuestos para el tratamiento de enfermedades oculares asociadas a una vascularización excesiva
CA3169975A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
CN113666985A (zh) * 2021-10-22 2021-11-19 山东谷雨春生物科技有限公司 一种曲安奈德的制备方法
AU2022371727A1 (en) 2021-10-22 2024-05-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
CN116023321A (zh) * 2022-12-30 2023-04-28 中国药科大学 Sting抑制剂前药及其医药用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8613591D0 (en) * 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
ATE480539T1 (de) 2000-08-10 2010-09-15 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IL154993A0 (en) 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
DE10231783A1 (de) 2001-07-19 2003-03-20 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) * 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SI2381778T1 (sl) 2008-12-22 2016-10-28 Chemocentryx, Inc. Antagonisti C5AR
KR20120092096A (ko) 2009-09-02 2012-08-20 머크 샤프 앤드 돔 코포레이션 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ｉｖ 억제제로서의 아미노테트라히드로피란
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EA201590379A1 (ru) 2012-08-16 2015-06-30 Янссен Фармацевтика Нв Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
US10683294B2 (en) * 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
US10759807B2 (en) 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
BR112020012270A2 (pt) 2017-12-22 2020-11-24 Chemocentryx, Inc. compostos de anel 6,5-fundido substituído por diarila como inibidores de c5ar
MX2020010390A (es) 2018-04-02 2021-01-15 Chemocentryx Inc Profarmacos de antagonistas de c5ar biciclicos fusionados.

Also Published As

Publication number Publication date
US11608336B2 (en) 2023-03-21
SG11202009588PA (en) 2020-10-29
KR20200139751A (ko) 2020-12-14
CA3095184A1 (en) 2019-10-10
WO2019195159A1 (en) 2019-10-10
BR112020019822A2 (pt) 2021-03-16
RU2020135500A (ru) 2022-05-05
MA52245A (fr) 2021-04-28
EP3773563A4 (en) 2021-12-29
AR114464A1 (es) 2020-09-09
US20210052612A1 (en) 2021-02-25
EP3773563A1 (en) 2021-02-17
JP7337833B2 (ja) 2023-09-04
IL277608B2 (en) 2023-09-01
TW202002966A (zh) 2020-01-16
TWI827590B (zh) 2024-01-01
US20190300526A1 (en) 2019-10-03
IL277608B1 (en) 2023-05-01
JP2021519794A (ja) 2021-08-12
IL277608A (en) 2020-11-30
AU2019246969A1 (en) 2020-10-15
CN111954525A (zh) 2020-11-17
CN111954525B (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
MX2020010390A (es) Profarmacos de antagonistas de c5ar biciclicos fusionados.
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
NZ737399A (en) Ccr2 modulators
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020001236A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PH12018500627A1 (en) Compounds and compositions for the treatment of ocular disorders
MX2020003185A (es) Nuevos compuestos heterociclicos.
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018001636A (es) Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5,-trifluoro-3,4,5,6-tetrahidropiridinas.
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
PH12017501736A1 (en) Indole derivatives
PH12018502490A1 (en) Oral tipepidine preparation
MX2020007271A (es) Sales y cristales novedosos.
TR201719926A2 (tr) Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler